Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag ADR (OP:BAYRY)

9.880 -0.270 (-2.66%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
AI To Revolutionize Clinical Trials And Diagnostics ↗
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
News headline image
From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
News headline image
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch ↗
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for... 
Via Benzinga
News headline image
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Daily Stock Analysis: Bayer AG - May '23 Update ↗
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as over the counter products. 
Via Talk Markets
News headline image
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals ↗
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
Via Benzinga
News headline image
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness ↗
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
News headline image
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? ↗
Tiziana Life Sciences, Inc. 
Via Benzinga
News headline image
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,... 
Via Benzinga
News headline image
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in... 
Via Benzinga
News headline image
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
News headline image
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study ↗
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced  
Via Benzinga
News headline image
Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters ↗
 
Via Benzinga
News headline image
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender ↗
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday. 
Via Investor's Business Daily
News headline image
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst ↗
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a  
Via Benzinga
News headline image
Unmasking Q2 2023's Stars & Strugglers: Industry ETFs And Top Stock Standouts ↗
 
Via Benzinga
News headline image
There’s Only One Way To Beat The Market ↗
The way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. Today, I want to show you how savvy stock pickers can profit from... 
Via Talk Markets
News headline image
Perrigo Picks Former Bayer Executive As New CEO ↗
Perrigo Co PLC (NYSE: PRGO) disclosed the appointment of Patrick Lockwood-Taylor as its new President, CEO and member of the Board of Directors, 
Via Benzinga
News headline image
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries ↗
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present... 
Via Talk Markets
News headline image
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗
 
Via Benzinga
News headline image
After That Big Merger, What Happened? ↗
There are often substantial controversies over whether a merger should be allowed to happen, but then relatively little follow-up after the event. 
Via Talk Markets
InvestorNewsBreaks – ROTH MKM’s Agribusiness Investment Banking Group Serves as Sellside Advisor for Three M&A Transactions
Via Investor Brand Network
Topics Derivatives
News headline image
Russia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories ↗
Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning 
Via Benzinga
News headline image
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities ↗
 
Via Benzinga
News headline image
Evogene Offers An Excellent Risk/Reward Ratio ↗
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
News headline image
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B ↗
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years. 
Via Benzinga
News headline image
EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue ↗
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among... 
Via Benzinga
News headline image
Bayer Snags Ex-Roche Exec Bill Anderson As New CEO; Shares Rocket ↗
Bill Anderson, who previously headed up Roche's pharma division, will take over June 1. 
Via Investor's Business Daily
News headline image
Investors Always Miss This Key Element ↗
Return on invested capital, or ROIC, is one of the most critical inputs needed to figure out the value of a company. 
Via Talk Markets
News headline image
Ring The Register; Plus, Where To Park Your Profits ↗
Sometimes an investment works out a lot quicker than expected. That’s the case with my July 2022 pick, Freeport-McMoRan Inc., the fourth-largest copper mining company in the world. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.